Mizuho lowered the firm’s price target on Nkarta (NKTX) to $16 from $20 and keeps an Outperform rating on the shares. The analyst updated models in the biotechnology group following the Q3 reports. The firm removed the potential contribution of NKX019 in large B-cell malignancies, upon Nkarta announcing that it will no longer further development in this indication.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTX: